Strategic Performance Drivers
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
Delivered broad-based growth across all segments, driven by a deliberate enterprise-wide focus on margin recovery and operational discipline.
Aetna’s performance reflects the cumulative impact of coordinated actions over two years, resulting in over $2 billion of year-over-year improvement in adjusted operating income.
CVS Pharmacy has established itself as the ‘best-run national pharmacy’ through intentional investments in technology and colleague engagement, leading to consistent script growth and service excellence.
Strategic positioning in the GLP-1 market utilizes a multi-channel approach, capturing volume through funded benefits while expanding direct-to-consumer access via MinuteClinic and manufacturer partnerships.
The Health Services segment is navigating a transition toward greater transparency and net-cost pricing models, aiming to preserve PBM value while adapting to regulatory shifts.
Management is pivoting the company from a consumer-based healthcare provider to a consumer-based healthcare technology business, anchored by a $20 billion decade-long investment plan.
2027 Outlook and Strategic Assumptions
Established a preliminary 2027 adjusted EPS floor of $8.44, representing approximately 13% growth from the 2026 adjusted baseline.
Expects continued momentum in Aetna’s margin recovery over the next few years, supported by disciplined pricing and medical cost management in Medicare Advantage.
Anticipates 2027 headwinds in the Health Services segment due to ongoing 340B program dynamics and a more disciplined approach to PBM client renewals and underwriting.
Assumes a robust generic and biosimilar pipeline in 2027 will serve as a significant tailwind for the industry-leading specialty pharmacy business.
Guidance philosophy remains focused on credible targets and disciplined execution, with capital deployment currently limited to offsetting dilution until leverage improves.
Risk Factors and Structural Dynamics
The 340B program remains a dynamic risk as pharmaceutical manufacturers impose restrictions on covered entities, impacting purchasing economics.
Challenging unconstitutional pharmacy laws in states like Arkansas and Tennessee that management believes threaten care accessibility and affordability.
The transition to the CVS CostVantage model is intended to stabilize pharmacy reimbursement and align more closely with payer value, though it requires careful execution.
Aetna’s exit from the individual exchange business in 2026 resulted in a year-over-year membership decline of approximately 700,000 members.
